Shaping a sustainable and safe food supply

Webcast 29 November 2023, 15h00 CET

Kevin Helash (CEO) Douglas Minder (CFO) Carlo Boutton (CSO)



Disclaimer



This presentation, including the oral presentation (together, the "Materials") has been prepared by the management of Biotalys NV (the "Company"). The Materials must be treated confidentially and may not be distributed, passed on or otherwise disclosed. The Materials serve information purposes only and do not constitute a prospectus or any offer for sale or subscription of, or solicitation or invitation to buy or subscribe for, any securities of the Company's business, operations, financial situation and prospects are subject to risks and uncertainties. A description of the most important risks and uncertainties can be found in the Company's annual report available on its website (www.Biotalys.com)

This presentation includes market share and industry data, which were obtained by the Company from industry publications, press releases, data published by government agencies, industry reports prepared by consultants and other market data providers and internal surveys. The third party sources the Company has used generally state that the information they contain has been obtained from sources believed to be reliable. Some of these third party sources also state, however, that the accuracy and completeness of such information is not guaranteed and that the projections they contain are based on significant assumptions. As the Company does not have access to the facts and assumptions underlying such market data, or statistical information and economic indicators contained in these third party sources, the Company is unable to verify such information and, while the Company believes it to be reliable, it cannot guarantee its accuracy or completeness.

In addition, certain information in this document is not based on published data obtained from independent third parties or extrapolations therefrom, but rather is based upon the Company's best estimates, which are in turn based upon information obtained from trade and business organizations and associations, consultants and other contacts within the industries in which the Company operates, information published by its competitors and its own experience and knowledge of conditions and trends in the markets in which it operates. The Company cannot provide any assurance that any of the assumptions that it has made while compiling this data from third party sources are accurate or correctly reflect its position in the industry and none of its internal estimates have been verified by any independent sources. The Company makes no representation or warranty as to the accuracy or completeness of this information. The Company has not independently verified this information and, while the Company believes it to be reliable, it cannot guarantee its accuracy.

You are responsible for protecting yourself against viruses and other destructive items. You are accessing the Materials is at your own risk and it is your responsibility to take precautions to ensure that they are free from viruses or other items of a destructive nature.

The Materials are provided in conjunction with the oral presentation held by the Company and should not be taken out of context.

The information contained in the Materials is subject to change without prior notice. The presentation of the Materials (or any part hereof) shall not create any implication that there has been no change in the information contained in the Materials since the date hereof or that there has been no change in the business or financial position of the Company or its subsidiary since the date hereof. The Company does not undertake to provide any additional information, update or keep current information contained in the Materials, or to remedy any omissions in or from the Materials and any opinions expressed in the Materials are subject to change without prior notice. The foregoing is in any event without prejudice to the Company's obligations under applicable law in relation to disclosure.

The Materials contain certain forward-looking statements, sometimes identified by the words "believes," "expects," "intends," "projects," "plans," "estimates," "anticipates," "anticipates," and similar expressions, which speak only as at the date of the Materials. Such statements reflect current views with respect to future events and are subject to risks and uncertainties. Forward-looking statements are based on current plans, estimates, projections and expectations. These statements are based on certain assumptions that may prove to be erroneous. No representations or warranties, express or implied, are given as to the achievement or reasonableness of, and no reliance should be placed on, such forward-looking statements, including any projections, estimates forecasts or targets contained herein.

Nothing in this presentation constitutes an offer of securities for sale in the EEA, the United Kingdom, Switzerland, Japan, the United States or elsewhere. The securities of the Company are not registered under the U.S. Securities Act of 1933, as amended (the "Securities Act") and may not be offered, sold or otherwise transferred within the United States (as such term is defined in Regulation S under the Securities Act) unless registered under the Securities Act or pursuant to an exemption from such registration. There is no intention to register securities of the Company under the Securities Act.

You acknowledge that all industrial and intellectual property rights to this presentation are and shall remain vested in the Company. By attending this presentation or accessing the Materials you shall not acquire any right, title, license to use, or interest in the presentation or the Materials.

All of the trademarks, service marks and logos displayed in the Materials, including but not limited to Biotalys, AGROBODY, EVOCA are registered and unregistered trademarks of the Company or one of its affiliates. Except as expressly provided in the Materials, you may not reproduce, display or otherwise use trademarks without first obtaining the Company's written permission.



Agenda

- AGROBODY Foundry[™] 2.0: a next-generation technology platform
- Aligned pipeline of product candidates
- Update on the regulatory review of EVOCA[™]
- Leadership and organisation fit for purpose
- Cost management and adjusted cash burn guidance for FY2023





Why invest in Biotalys now?

Groundbreaking technology – based on large-molecule antibodies successfully used in pharma industry Novel modes of action to provide growers new crop protection alternatives with industry-leading ROIs

Evoca[™] biofungicide first-generation product candidate from AGROBODY Foundry[™] platform serving high-growth agriculture market

Cost-efficient R&D focused on advancing novel solutions to unlock multiple iterations of new modes of action in fungicides and insecticides

Regulatory processes advancing in USA and EU


Commercial agreements for production and marketing in place or in process

Led by experienced management team, board and scientific advisors

Continued cost management coupled with exploration of revenue streams from partnerships




AGROBODY Foundry™ 2.0: from platform validation to a next generation of the technology platform





A more targeted discovery approach

Separate the wheat from the chaff early in the AGROBODY[™] discovery process





Innovative pipeline focusing on biofungicides and bioinsecticides

ණි Program	🛱 Туре	🕒 Market	🕑 Status
EVOCA [™] 1 st generation	Biofungicide (botrytis, powdery mildew)	High-value fruits & vegetables	Currently under review by regulatory authorities in US and EU
EVOCA [™] Next generation	Biofungicide (botrytis, powdery mildew)	High-value fruits & vegetables	Developed to have broader application and market penetration
Pipeline	Biofungicides & bioinsecticides (a variety of key diseases and pests)	Fruits & vegetables, legumes, etc.	Targeted discovery approach Partnerships in place or being explored



Aligned pipeline of product candidates

Other ongoing programs next to EVOCA and EVOCA NG

- **BioFun-4**, aimed at targeting Oomycetes in fruits and vegetables
- **BioFun-6**, aimed at targeting botrytis, powdery mildew and anthracnose in fruits and vegetables
- **BioFun-7**, aimed at targeting leafspot disease in cowpeas and other legumes, in collaboration with the Bill & Melinda Gates Foundation
- BioIns-2, aimed at targeting key pests, in collaboration with Syngenta Crop Protection

New programs

• Expectation to initiate **at least 1 new program per year** on the AGROBODY Platform 2.0.

Discontinued programs

- **BioBac-1**, as no longer focus area
- BioIns-1, as focus on other insecticide program with Syngenta Crop Protection
- **BioFun-2**, as focus is on other programs in the high value fruit and vegetable segment



Regulatory approval process for EVOCA continues to advance

United States

- EPA regulatory review ongoing
- EPA asks questions on a regular basis and Biotalys continues its efforts to respond
- Working with industry experts to support the submission
- Novel nature of the technology requires in-depth review, but also sets standard for future approvals of protein-based biocontrols

European Union

- Dutch authority Ctgb concluded its first review
- Ctgb asks questions and Biotalys continues its efforts to respond
- If accepted, Ctgb will pass the file for a second review by EFSA and the EU Member States



Leadership aligned to focus on core capabilities





Cost management and adjusted cash burn guidance FY 2023

- Organisational changes announced today will result in annualised cost savings leading to an approximate 10% reduction in operating expenses going forward
- Management will carefully manage cost and resources going forward
- Revised expected cash for FY 2023 from slightly less than €22 million to less than €20 million



Why invest in Biotalys now?

Groundbreaking technology – based on large-molecule antibodies successfully used in pharma industry Novel modes of action to provide growers new crop protection alternatives with industry-leading ROIs

Evoca[™] biofungicide first-generation product candidate from AGROBODY Foundry[™] platform serving high-growth agriculture market

Cost-efficient R&D focused on advancing novel solutions to unlock multiple iterations of new modes of action in fungicides and insecticides

Regulatory processes advancing in USA and EU

Commercial agreements for production and marketing in place or in process

Led by experienced management team, board and scientific advisors

Continued cost management coupled with exploration of revenue streams from partnerships

